We are pleased to announce that as of today, Purple Vigilance is able to offer a new service; we can now assist Marketing Authorisation Holders (MAHs) and Sponsors with data entry and maintenance of products details in the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD).
Background on the XEVMPD
One of the key deliverables of the 2010 Pharmacovigilance legislation relates to the submission by MAHs of information about medicines to the European Medicines Agency (EMA). The requirement is described in Article 57(2) of Regulation (EC) No 1235/2010.
Purple Vigilance can enter the details of your products onto XEVMPD and provide on-going maintenance to ensure continued compliance.
Contact us now to discuss your requirements!
Purple Vigilance is 1 year old! It’s been a year since Purple Vigilance was incorporated and what an eventful year it has been. 2012 has seen the implementation of biggest change in EU Pharmacovigilance (PV) legislation and regulation of human medicines in the European Union since 1995.
Purple Vigilance has completed a wide range of projects in the last year, from training on the new legislation to preparing templates for common PV documents. Purple Vigilance is providing on-going PV support to several companies in addition to EU QPPV services.
I would like to thank all of Purple Vigilance’s clients for your business and kind support over the last year – you have helped the business to be a success!
If your organisation has any PV needs, however small, please do not hesitate to contact us for advice.
The EMA has published a Q and A document on transitional arrangements for the new pharmacovigilance legislation in preparation for July 2012.
The document addresses some of the questions that Marketing Authorisation Holders may have on areas such as the pharmacovigilance system master file, risk management plans and the submission of renewals.
The document can be found by following the link below:
The MHRA is inviting comments on the transposition of the Pharmacovigilance Directive 2010/84/EU into UK law. The new PV legislation comes into force in July 2012 and the documents provided by the MHRA give an insight into the proposals for UK.
Comments should be provided to the MHRA by 28th February 2012.
More information can be found by the following the link below:
The MHRA has published an update to the Good Pharmacovigilance Practice section of their website. The update concerns the publication and distribution of updated Summaries of product Characteristics (SPCs) and Patient Information Leaflets (PILs) following safety-related changes. The MHRA recommends specific timeframes for completing activities relating to updated SPCs and PILs, following findings by the GPvP Inspectorate.
It is important for Marketing Authorisation Holders to note the expectations of the MHRA relating to timeframes for publication and distribution of these documents, to ensure timely risk communication to internal and external customers.
More information on the guidance published by the MHRA can be found by following the link below:
The MHRA are no longer sending out Anonymised Single Patient Reports (ASPRs)/ Individual Case Safety Reports (ICSRs) from literature to Marketing Authorisation Holders (MAHs). This came about after a review by the BROMI Vigilance Workstream and should increase efficiency for both the MHRA and MAH Pharmacovigilance systems. The MHRA state that the number of ASPRs sent out to companies could be reduced by 33-50%. This will be of particular interest to generic companies that hold numerous Marketing Authorisations in the UK.
The MHRA have published information about this which can be found by following the link below. It is important to continue reporting serious cases from literature in line with the MHRA’s instructions & Volume 9a to ensure continued compliance. If you have any questions about ASPRs and how to manage them, please contact us and we will be happy to help you.
The GPvP Risk Based Inspection Compliance Reports are due for submission to the MHRA by 4th November 2011 – please mark this date in your diary! Completion of the report is not mandatory but the MHRA recommend that Marketing Authorisation Holders do complete one. If you do not submit a completed report the MHRA will assign your company a high risk rating, increasing your chances of a Pharmacovigilance Inspection. More information can be found at
We are very proud to announce that Purple Vigilance Limited, a Pharmacovigilance Consultancy, was established in September 2011. This website is under construction and will be completed soon, please check back regularly for updates. Please see the About Us and PV Services page for more information. Please feel free to contact us to discuss your current or future requirements.